Cargando…
A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol
INTRODUCTION: There are currently no effective treatments preventing conversion from mild cognitive impairment (MCI) to Alzheimer's disease. Cilostazol is a selective type-3 phosphodiesterase inhibitor that ameliorates accumulation of amyloid-β and has prevented cognitive decline in rodent mode...
Autores principales: | Saito, Satoshi, Kojima, Shinsuke, Oishi, Naoya, Kakuta, Ryosuke, Maki, Takakuni, Yasuno, Fumihiko, Nagatsuka, Kazuyuki, Yamamoto, Haruko, Fukuyama, Hidenao, Fukushima, Masanori, Ihara, Masafumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651350/ https://www.ncbi.nlm.nih.gov/pubmed/29067312 http://dx.doi.org/10.1016/j.trci.2016.10.001 |
Ejemplares similares
-
Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial
por: Saito, Satoshi, et al.
Publicado: (2023) -
Significant correlation between openness personality in normal subjects and brain myelin mapping with T1/T2-weighted MR imaging
por: Yasuno, Fumihiko, et al.
Publicado: (2017) -
Simultaneous infrared thermal imaging and laser speckle imaging of brain temperature and cerebral blood flow in rats
por: Suzuki, Takashi, et al.
Publicado: (2018) -
Motor recovery and microstructural change in rubro-spinal tract in subcortical stroke()
por: Takenobu, Yohei, et al.
Publicado: (2013) -
The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice
por: Nakaoku, Yuriko, et al.
Publicado: (2019)